Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering ...
Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will ...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of ...
-Presentations will include latest data from Factor's IL12-expressing iMacrophages for treating solid tumors (FACT-112), as ...
Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations ...
The Supreme Court has heard arguments in a case about the Trump administration’s push to end legal protections for migrants ...
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of ...
Hypervigilance: A phase Ib clinical trial to optimize risk-benefit of nezastomig (PSMAxCD28 costimulatory bispecific antibody) plus cemiplimab (anti-PD-1) in patients with metastatic ...
Researchers have identified special immune cells in the brain that help slow Alzheimer's disease. These microglia work to reduce inflammation and block the spread of harmful proteins. They appear to ...
Researchers have identified special immune cells in the brain that help slow Alzheimer’s. These microglia work to reduce inflammation and block the spread of harmful proteins. They appear to protect ...
In Alzheimer’s disease, the leading cause of dementia, microglia—the brain’s immune defenders—can act as both protectors and aggressors, shaping how the disease progresses. Researchers from the Icahn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results